Benjamin Garlipp1, Henry Ptok2,3, Frank Benedix2, Ronny Otto3, Felix Popp2, Karsten Ridwelski3,4, Ingo Gastinger3, Christoph Benckert2, Hans Lippert3, Christiane Bruns2,3. 1. Department of Surgery, Otto von Guericke University Hospital, Leipziger Str. 44, 39120, Magdeburg, Germany. Benjamin.garlipp@med.ovgu.de. 2. Department of Surgery, Otto von Guericke University Hospital, Leipziger Str. 44, 39120, Magdeburg, Germany. 3. Institute for Quality Assurance in Surgery, Otto von Guericke University, Leipziger Str. 44, 39120, Magdeburg, Germany. 4. Department of Surgery, Magdeburg City Hospital, Birkenallee 34, 39130, Magdeburg, Germany.
Abstract
AIMS: Adjuvant chemotherapy for resected rectal cancer is widely used. However, studies on adjuvant treatment following neoadjuvant chemoradiotherapy (CRT) and total mesorectal excision (TME) have yielded conflicting results. Recent studies have focused on adding oxaliplatin to both preoperative and postoperative therapy, making it difficult to assess the impact of adjuvant oxaliplatin alone. This study was aimed at determining the impact of (i) any adjuvant treatment and (ii) oxaliplatin-containing adjuvant treatment on disease-free survival in CRT-pretreated, R0-resected rectal cancer patients. METHOD: Patients undergoing R0 TME following 5-fluorouracil (5FU)-only-based CRT between January 1, 2008, and December 31, 2010, were selected from a nationwide registry. After propensity score matching (PSM), comparison of disease-free survival (DFS) using Kaplan-Meier analysis and log-rank test was performed in (i) patients receiving no vs. any adjuvant treatment and (ii) patients treated with adjuvant 5FU/capecitabine without vs. with oxaliplatin. RESULTS: Out of 1497 patients, 520 matched pairs were generated for analysis of no vs. any adjuvant treatment. Mean DFS was significantly prolonged with adjuvant treatment (81.8 ± 2.06 vs. 70.1 ± 3.02 months, p < 0.001). One hundred forty-eight matched pairs were available for analysis of adjuvant therapy with or without oxaliplatin, showing no improvement in DFS in patients receiving oxaliplatin (76.9 ± 4.12 vs. 79.3 ± 4.44 months, p = 0.254). Local recurrence rate was not significantly different between groups in either analysis. CONCLUSION: In this cohort of rectal cancer patients treated with neoadjuvant CRT and TME surgery under routine conditions, adjuvant chemotherapy significantly improved DFS. No benefit was observed for the addition of oxaliplatin to adjuvant chemotherapy in this setting.
AIMS: Adjuvant chemotherapy for resected rectal cancer is widely used. However, studies on adjuvant treatment following neoadjuvant chemoradiotherapy (CRT) and total mesorectal excision (TME) have yielded conflicting results. Recent studies have focused on adding oxaliplatin to both preoperative and postoperative therapy, making it difficult to assess the impact of adjuvant oxaliplatin alone. This study was aimed at determining the impact of (i) any adjuvant treatment and (ii) oxaliplatin-containing adjuvant treatment on disease-free survival in CRT-pretreated, R0-resected rectal cancerpatients. METHOD:Patients undergoing R0 TME following 5-fluorouracil (5FU)-only-based CRT between January 1, 2008, and December 31, 2010, were selected from a nationwide registry. After propensity score matching (PSM), comparison of disease-free survival (DFS) using Kaplan-Meier analysis and log-rank test was performed in (i) patients receiving no vs. any adjuvant treatment and (ii) patients treated with adjuvant 5FU/capecitabine without vs. with oxaliplatin. RESULTS: Out of 1497 patients, 520 matched pairs were generated for analysis of no vs. any adjuvant treatment. Mean DFS was significantly prolonged with adjuvant treatment (81.8 ± 2.06 vs. 70.1 ± 3.02 months, p < 0.001). One hundred forty-eight matched pairs were available for analysis of adjuvant therapy with or without oxaliplatin, showing no improvement in DFS in patients receiving oxaliplatin (76.9 ± 4.12 vs. 79.3 ± 4.44 months, p = 0.254). Local recurrence rate was not significantly different between groups in either analysis. CONCLUSION: In this cohort of rectal cancerpatients treated with neoadjuvant CRT and TME surgery under routine conditions, adjuvant chemotherapy significantly improved DFS. No benefit was observed for the addition of oxaliplatin to adjuvant chemotherapy in this setting.
Authors: E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde Journal: N Engl J Med Date: 2001-08-30 Impact factor: 91.245
Authors: Anne J Breugom; Marloes Swets; Jean-François Bosset; Laurence Collette; Aldo Sainato; Luca Cionini; Rob Glynne-Jones; Nicholas Counsell; Esther Bastiaannet; Colette B M van den Broek; Gerrit-Jan Liefers; Hein Putter; Cornelis J H van de Velde Journal: Lancet Oncol Date: 2015-01-12 Impact factor: 41.316
Authors: Deborah Schrag; Martin R Weiser; Karyn A Goodman; Mithat Gonen; Ellen Hollywood; Andrea Cercek; Diane L Reidy-Lagunes; Marc J Gollub; Jinru Shia; Jose G Guillem; Larissa K F Temple; Philip B Paty; Leonard B Saltz Journal: J Clin Oncol Date: 2014-01-13 Impact factor: 44.544
Authors: A J Breugom; W van Gijn; E W Muller; Å Berglund; C B M van den Broek; T Fokstuen; H Gelderblom; E Kapiteijn; J W H Leer; C A M Marijnen; H Martijn; E Meershoek-Klein Kranenbarg; I D Nagtegaal; L Påhlman; C J A Punt; H Putter; A G H Roodvoets; H J T Rutten; W H Steup; B Glimelius; C J H van de Velde Journal: Ann Oncol Date: 2014-12-05 Impact factor: 32.976
Authors: P Hermanek; P Hermanek; W Hohenberger; M Klimpfinger; F Köckerling; T Papadopoulos Journal: Int J Colorectal Dis Date: 2003-02-14 Impact factor: 2.571
Authors: B Fisher; N Wolmark; H Rockette; C Redmond; M Deutsch; D L Wickerham; E R Fisher; R Caplan; J Jones; H Lerner Journal: J Natl Cancer Inst Date: 1988-03-02 Impact factor: 13.506
Authors: Per J Nilsson; Boudewijn van Etten; Geke A P Hospers; Lars Påhlman; Cornelis J H van de Velde; Regina G H Beets-Tan; Lennart Blomqvist; Jannet C Beukema; Ellen Kapiteijn; Corrie A M Marijnen; Iris D Nagtegaal; Theo Wiggers; Bengt Glimelius Journal: BMC Cancer Date: 2013-06-07 Impact factor: 4.430